Skip to content
drillr.ai
Sign up

002693.SZ

Hainan Shuangcheng Pharmaceuticals Co., Ltd.

SZSE · Healthcare · C 制造业 · CN

CNY 8.64
+0.47%
Ask drillr

  • Oct 22, 2026, 12:49 UTC

    Shuangcheng Pharmaceutical disclosed that director and executives LI JIANMING, Yuan Jianlin, Ai Yixiang, and Wang Rui sold 240,000, 81,000, 18,000, and 15,525 shares, respectively, under a share-reduction plan that expired on October 21, 2026.

    Source:

  • Sep 14, 2026, 08:20 UTC

    Shuangcheng Pharmaceutical's controlling shareholder Hainan Shuangcheng Investment Co., Ltd. completed a name change to Hainan Shuangcheng Investment Group Co., Ltd. and a change of business scope, with registered capital of 10 million yuan, without any change in shareholding or actual controller.

    Source:

  • Aug 21, 2026, 10:23 UTC

    Shuangcheng Pharmaceutical announced its first-half 2026 results: revenue of 117 million yuan, up 39.27% year-on-year; net profit attributable to shareholders of 13.63 million yuan, versus a net loss of 18.47 million yuan a year earlier; non-recurring-adjusted net profit of 10.90 million yuan, versus a loss of 21.02 million yuan a year earlier. The company declared no cash dividend, no bonus shares, and no capital reserve conversion.

    Source:

  • Aug 5, 2026, 11:23 UTC

    Shuangcheng Pharmaceutical's deputy general manager Yao Zhong reduced his shareholding in the company by 40,500 shares through centralized bidding on August 4, 2026, accounting for 0.01% of total share capital, at an average price of 9.65 yuan per share, completing the reduction plan.

    Source:

  • Jul 31, 2026, 09:15 UTC

    Shuangcheng Pharmaceutical received a government subsidy of 2.3513 million yuan on July 31, 2026, accounting for 12.35% of its latest audited net profit attributable to shareholders; the subsidy was in cash, related to daily operations, and not sustainable.

    Source: